Source: European Medicines Agency (EU) Revision Year: 2013 Publisher: Astellas Pharma Europe B.V., Sylviusweg 62, 2333 BE Leiden, The Netherlands
Vasexten 10, 10 mg modified release capsules.
| Pharmaceutical Form |
|---|
|
Modified release capsules, hard. Vasexten 10 modified release capsules are yellow and marked: 155 10 |
Vasexten contains barnidipine hydrochloride.
Vasexten 10 modified release capsules, hard, contain 10 mg barnidipine hydrochloride, equivalent to 9.3 mg barnidipine per capsule.
Excipients with known effect: sucrose 95 mg.
For the full list of excipients, see section 6.1
| Active Ingredient |
|---|
|
Barnidipine is a lipophilic 1,4-dihydropyridine calcium antagonist showing high affinity for the calcium channels of the smooth muscle cells in the vascular wall. |
| List of Excipients |
|---|
|
The excipients of Vasexten capsules are: Capsule content: carboxymethylethylcellulose, polysorbate 80, sucrose, ethylcellulose, talc. Capsule shell: titanium dioxide (E171), yellow iron oxide (E172) and gelatine. Printing ink: shellac, propylene glycol (E1520), black iron oxide (E172), ammonia. |
Vasexten modified release capsules are packed in boxes containing 10, 14, 20, 28, 30, 50, 56, 98 or 100 capsules in aluminium-aluminium (with PVC and polyamide coating) blisters. A blister contains 7, 10 or 14 capsules.
Not all pack sizes may be marketed.
Astellas Pharma Europe B.V., Sylviusweg 62, 2333 BE Leiden, The Netherlands
| Drug | Countries | |
|---|---|---|
| VASEXTEN | Netherlands |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.